Articles

Why Trump’s ‘Great Healthcare Plan’ strikes Wall Street as so underwhelming

The Trump administration on Thursday rolled out what it’s calling the “Great Healthcare Plan,” with elements that include funding for health savings accounts and a call for Congress to write into law the pricing deals that President Trump has made with drugmakers.

There’s one thing that could make Trump’s ‘Great Healthcare Plan’ perfect

President Trump has at long last unveiled his healthcare plan, putting “great” in its name. Here’s how it could be better.

This stock- and bond blend made double-digit gains last year — yet too many investors dismiss it

Why we should sing the praises of the tried-and-true 60/40 stocks-bonds portfolio.

Verizon blames ‘software issue’ for outage — but specifics remain sparse

Verizon says a “software issue” is to blame for an outage that caused frustration in Northeast U.S. cities.

Anthropic’s Claude Cowork is a fresh drag on software stocks. Are investors overreacting?

Anthropic’s new tool has some on Wall Street even more fearful that traditional software will become obsolete. Others see a buying opportunity.

Why Nvidia’s stock isn’t partying like other parts of the chip sector this year

Nvidia’s stock is lagging semiconductor peers in the wake of TSM earnings — underscoring both its well-trodden narrative and the self-reinforcing outperformance of memory stocks.

Inflation relief is on the way — if these 3 market forces can come together this year

Productivity gains, tame oil prices and lower taxes could ease the pressure on consumers.

Mortgage rates fall to lowest level in over 3 years as home-buying activity picks up

It’s a major shift from where rates were a year ago: Last January, the 30-year rate averaged 7.04%.

Gen Z men believe they’ll buy a home someday — but see their finances getting worse. What gives?

Homeownership, marriage and parenthood are highly valued goals — and a tall order in today’s economy.

Why Rocket Lab’s stock could cool off after a blistering 263% rally in the past year

Rocket Lab’s stock price already reflects the impact of major recent milestones and renewed enthusiasm for the space sector, a KeyBanc analyst argues.

Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead

New research has found that 50% of patients regain the weight they lost if they stop taking Wegovy and Zepbound

These under-the-radar stocks combine fast growth with big upside potential

The companies are projected to grow sales rapidly through 2027, and many of the stocks are expected to show double-digit increases this year.
1 3 4 5 6 7 2,541